Arkansas Cardiology | Little Rock

Research site

(Unclaimed)

Location

9501 Baptist Health Drive Suite 600, Little Rock, Arkansas, United States of America

Site insights

Top conditions

Top treatments

Etripamil

Relugolix

Evolocumab

Methotrexate

IONIS-AGT-LRx

Droxidopa

Maridebart Cafraglutide

TNX-102

Ranolazine

Inclisiran

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 25 total trials

Encore PFO Closure Device - The PerFOrm Trial

The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when c...

Enrolling

Cryptogenic Stroke

Patent Foramen Ovale

Device: FDA-approved PFO closure device

Device: Encore PFO closure device

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function (PROTECT IV)

The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided hea...

Active, not recruiting

Coronary Artery Disease

Left Ventricular Dysfunction

Device: Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®

Device: IABP Intra-aortic balloon pump

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous co...

Enrolling

Peripheral Endovascular Intervention

Percutaneous Coronary Intervention

Drug: Normal Saline (Placebo)

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Locations recently updated

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF...

Enrolling

Heart Failure With Preserved Ejection Fraction

Obesity

Drug: Placebo

Drug: Maridebart cafraglutide

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in...

Active, not recruiting

Chronic Kidney Diseases

Hypertension

Device: Renal Denervation (Symplicity Spyral™)